Compare PayPal Holdings, Inc. (PYPL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PayPal Holdings, Inc. trades at $55.05 (market cap $47.07B), while State Street SPDR S&P Biotech ETF trades at $149.8 (market cap $10.11B). The key difference: PayPal Holdings, Inc. is far larger — about 4.7× State Street SPDR S&P Biotech ETF's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold PayPal Holdings, Inc. for 106 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PYPL | XBI | |
|---|---|---|
Market Cap | $47.07B | $10.11B |
Volume | 13,860,099 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $75.75 | $169.55 |
52-Week Low | $39.08 | $104.99 |
Typical Hold Time | 106 Days | 37 Days |
Enterprise Value | $49.21B | — |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $54.95, up 0.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a net income margin of 14.36% and ROE of 24.5%, supported by recent earnings beats in Q1 and Q2 2026. A new partnership with Meta's AI agent for checkout services, announced on September 22, 2026, provides a potential growth catalyst amid competitive pressures in digital payments.
PYPL presents a value opportunity with a low P/E of 10.39 and solid cash flow, but faces risks from slowing branded checkout growth and intense fintech competition. The stock's upside hinges on successful execution of Venmo expansion and cost-cutting initiatives under new CEO Enrique Lores, with investor sentiment cautiously optimistic given the 35.71% buy rating from analysts.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
